Hennion & Walsh Asset Management, Inc.
Position in AKBA — Akebia Therapeutics, Inc.
CIK 1861642
Parsippany, NJ
Position in AKBA
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$957,291
+$77,070 QoQ
Shares Held
839,729
+32.6% QoQ
Ownership
0.303%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#22
of 170 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Hennion & Walsh Asset Management, Inc. holds $46,273,762 across 11 Drug Manufacturers - Specialty & Generic names. AKBA ranks #10 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INDV |
Indivior Pharmaceuticals, Inc.
|
360,245 | $14,780,852 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
327,801 | $11,105,897 | |
| 3 | PCRX |
Pacira BioSciences, Inc.
|
203,520 | $5,163,302 | |
| 4 | SUPN |
Supernus Pharmaceuticals, Inc.
|
90,213 | $4,195,806 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
6,097 | $3,303,537 | |
| 6 | ALKS |
Alkermes plc.
|
47,317 | $2,479,410 | |
| 7 | VTRS |
Viatris Inc
|
104,642 | $1,661,714 | |
| 8 | BCRX |
Biocryst Pharmaceuticals Inc
|
112,893 | $1,128,930 |
All Filings in AKBA
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $957,291 | 839,729 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $880,221 | 633,253 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $803,327 | 498,961 | Shares | Sole | 2026-01-14 | |
| No filing history on record for this holder in this stock. | ||||||